Education
About Us
Working with TipRanks
Follow Us
AEON Biopharma (AEON)
:AEON
AEON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.38 - $269.28
Previous CloseN/A
Volume17.80M
Average Volume (3M)1.42M
Market Cap
$8.58M
Enterprise Value$121.79M
Total Cash (Recent Filing)$13.00K
Total Debt (Recent Filing)$12.96M
Price to Earnings (P/E)<0.1
Beta1.80
Next Earnings
Aug 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.28
Shares Outstanding11,305,367
10 Day Avg. Volume279,121
30 Day Avg. Volume1,415,140
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap14.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.56
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
AEON Biopharma News
PremiumCompany Announcements
AEON Biopharma Holds Annual Stockholders Meeting
PremiumCompany Announcements
Aeon Biopharma Reports Positive Q1 2025 Earnings
PremiumCompany Announcements
AEON Biopharma Releases New Corporate Presentation
PremiumCompany Announcements
AEON Biopharma Appoints New CEO Robert Bancroft
PremiumCompany Announcements
AEON Biopharma Appoints Jost Fischer as Interim CEO
PremiumCompany Announcements
AEON Biopharma’s Strategic Progress and Financial TurnaroundPremiumCompany Announcements
AEON Biopharma Announces CEO Resignation and Interim AppointmentBulls Say, Bears Say
Bulls Say
Cost ManagementR&D expenses declined 50.8% YoY to $4.4M, which were below the estimate, indicating effective cost management.
Regulatory ApprovalAeon finds alignment with the FDA on key biosimilar pathway requirements, boosting confidence in potential regulatory approval.
Bears Say
Funding UncertaintyGiven the uncertainty in funding, the price target is adjusted to $5 from $6, reflecting potential financial challenges.
Production DependencyAeon relies on Daewoong to manufacture ABP-450, and any production issues with Daewoong could adversely impact Aeon.
Options Prices
Currently, No data available
---
Ownership Overview
16.05% Insiders
0.07% Mutual Funds
13.42% Other Institutional Investors
70.42% Public Companies and Individual Investors
AEON FAQ
What was AEON Biopharma’s price range in the past 12 months?
AEON Biopharma lowest stock price was $0.38 and its highest was $269.28 in the past 12 months.
What is AEON Biopharma’s market cap?
AEON Biopharma’s market cap is $8.58M.
When is AEON Biopharma’s upcoming earnings report date?
AEON Biopharma’s upcoming earnings report date is Aug 18, 2025 which is in 48 days.
How were AEON Biopharma’s earnings last quarter?
AEON Biopharma released its earnings results on May 14, 2025. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of N/A by $2.28.
Is AEON Biopharma overvalued?
According to Wall Street analysts AEON Biopharma’s price is currently Overvalued.
Does AEON Biopharma pay dividends?
AEON Biopharma does not currently pay dividends.
What is AEON Biopharma’s EPS estimate?
AEON Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AEON Biopharma have?
AEON Biopharma has 11,305,367 shares outstanding.
What happened to AEON Biopharma’s price movement after its last earnings report?
AEON Biopharma reported an EPS of $2.28 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2%.
Which hedge fund is a major shareholder of AEON Biopharma?
Among the largest hedge funds holding AEON Biopharma’s share is Saba Capital Management. It holds AEON Biopharma’s shares valued at 0.
Company Description
AEON Biopharma
AEON Biopharma (AEON) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapeutic treatments targeting neurological and gastroenterological disorders. The company is engaged in the research and development of therapeutic applications for botulinum toxin complex, aiming to address unmet medical needs in various indications such as chronic migraine, cervical dystonia, and other related conditions.
Technical Analysis
Oruka Therapeutics
―
Cytokinetics
―
Rigel
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Atara Biotherapeutics
―